Contrast-enhanced Ultrasound Market Segmentation:
Type Segment Analysis
In terms of type, the microbubble contrast agents segment is estimated to gain the largest contrast-enhanced ultrasound market share of 60% in the year 2035. The microbubble contrast agent segment growth can be accounted for on the back of increasing cases of liver-related diseases including cirrhosis and hepatocellular carcinoma.
Liver diseases often require precise imaging for accurate diagnosis and monitoring of lesions, and microbubble contrast agents enhance the visibility of vascular structures and lesions during ultrasound imaging. Around a 25% rise has been recorded annually in the incidence of hepatocellular carcinoma globally in the last decade, reported as per a study.
This rapid growth in liver diseases underscores the critical need for advanced imaging techniques, such as contrast-enhanced ultrasound with microbubble contrast agents, for effective diagnosis and management. Continuous advancements in ultrasound technology, including improvements in transducer design and image processing algorithms, are driving the growth of the microbubble contrast agents segment.
End Users Segment Analysis
Based on end users, the hospital segment is expected to garner the highest CAGR during the projected timeframe. Hospitals serve as primary centers for diagnosing and managing liver diseases, and the demand for CEUS in this segment is driven by the need for accurate and non-invasive imaging to assess liver lesions.
The hospital segment growth is assessed to rise due to increasing cardiovascular disease cases recorded globally. Hospitals play a central role in cardiovascular care, and the utilization of CEUS for cardiac imaging contributes to the comprehensive assessment of patients with conditions such as myocardial infarction, heart failure, and valvular disorders.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End User |
|
|
Technology |
|
